Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$47.46

0.09 (0.19%)

13:17
11/17/19
11/17
13:17
11/17/19
13:17

Data shows AstraZeneca's Brilinta reduces risks of clinically relevant bleeding

New results from a pre-specified subgroup analysis of the TWILIGHT trial showed that Brilinta monotherapy reduced the risk of clinically relevant bleeding compared to dual antiplatelet therapy, or DAPT, over 12 months in high-risk patients with non-ST elevation acute coronary syndromes. Results of the TWILIGHT sub-analysis were presented in a late breaker oral presentation on November 17 at the American Heart Association, or AHA, Scientific Sessions 2019 in Philadelphia. Danilo Verge, VP Global Medical Affairs, Cardiovascular, Renal and Metabolism said, "The TWILIGHT trial provided important information about the longer-term management of high-risk patients who had undergone PCI. In this pre-specified subgroup analysis of patients with NSTE-ACS enrolled in TWILIGHT, treatment with ticagrelor monotherapy, without aspirin, after three months of DAPT was associated with a lower risk of bleeding compared with standard 12 months of dual antiplatelet therapy with ticagrelor plus aspirin."

  • 18

    Nov

  • 07

    Dec

AZN AstraZeneca
$47.46

0.09 (0.19%)

11/05/19
JEFF
11/05/19
NO CHANGE
Target $75
JEFF
Buy
Jefferies sees nothing new in FibroGen short report
Jefferies analyst Michael Yee does not see "anything really new" in yesterday's short report on FibroGen. The report is all based on earlier small Phase II/III studies that are already known, as well as on studies in China/Japan, where the drug has recently been approved, Yee tells investors in a research note. Moreover, FibroGen partner AstraZeneca (AZN) has publicly stated it is comfortable with the data, adds Yee. He keeps a Buy rating on FibroGen shares with a $75 price target
11/10/19
PIPR
11/10/19
NO CHANGE
PIPR
Piper Jaffray sees approval for FibroGen's roxadustat, but still has concerns
Piper Jaffray analyst Danielle Brill maintained a Neutral rating and $42 price target on FibroGen (FGEN). After getting more color on the MACE data from a meeting with management, speaking to a lead investigator, and listening to AstraZeneca's (AZN) call, Brill continues to expect approval of the drug, but also sees aspects that will drive debate, and a lack of clarity until FDA briefing documents for an Ad Com panel are released next year, which could be 6-10 months from now depending on priority. The analyst also still questions whether the labeling for the drug, if it is approved, will include a black box safety warning.
11/12/19
JEFF
11/12/19
NO CHANGE
JEFF
Buy
Jefferies doesn't see 'anything new' in latest FibroGen short report
Jefferies analyst Michael Yee addressed some of the takeaways from "another short report" on FibroGen (FGEN), which he doesn't think includes "anything new." He has previously said that he expects ongoing "noise and confusion" about cardiovascular events in various populations, though he has talked to FibroGen, AstraZeneca (AZN) and many doctors and investigators, who "support a clear view of approval and safety here." The newest short report published on FibroGen highlights topics that are "generally known or mentioned in our previous reports," added Yee, who has a Buy rating on the shares.
11/15/19
GUGG
11/15/19
NO CHANGE
Target $228
GUGG
Buy
BeiGene price target raised to $228 from $205 at Guggenheim
Guggenheim analyst Michael Schmidt raised his price target for BeiGene (BGNE) to $228 from $205 saying FDA approval of Brukinsa over three months ahead of the action date provides additional validation of the company's strategy and ability to execute. He thinks Brukinsa's label in mantle cell lymphoma indicates a "potentially best-in-class" product profile with "nuanced differences" compared to AstraZeneca's (AZN) Calquence and "significantly better" than AbbVie's (ABBV) Imbruvica. The analyst maintains a Buy rating on BeiGene shares.

TODAY'S FREE FLY STORIES

GME

GameStop

$6.50

0.18 (2.85%)

05:33
12/11/19
12/11
05:33
12/11/19
05:33
Recommendations
GameStop analyst commentary  »

Baird cuts GameStop price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SWAV

ShockWave Medical

$40.43

-0.08 (-0.20%)

05:29
12/11/19
12/11
05:29
12/11/19
05:29
Recommendations
ShockWave Medical analyst commentary  »

ShockWave Medical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOL

Gol Linhas

$16.88

-0.83 (-4.69%)

, DAL

Delta Air Lines

$55.52

-0.27 (-0.48%)

05:26
12/11/19
12/11
05:26
12/11/19
05:26
Hot Stocks
Gol Linhas announces change in shareholding ownership »

GOL Linhas (GOL) hereby…

GOL

Gol Linhas

$16.88

-0.83 (-4.69%)

DAL

Delta Air Lines

$55.52

-0.27 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

JOUT

Johnson Outdoors

$75.16

-2.36 (-3.04%)

05:25
12/11/19
12/11
05:25
12/11/19
05:25
Recommendations
Johnson Outdoors analyst commentary  »

Johnson Outdoors price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$293.21

-9.27 (-3.06%)

05:24
12/11/19
12/11
05:24
12/11/19
05:24
Recommendations
Netflix analyst commentary  »

Piper analysis shows Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$44.26

2.3 (5.48%)

05:20
12/11/19
12/11
05:20
12/11/19
05:20
Recommendations
Agios Pharmaceuticals analyst commentary  »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

XBIT

XBiotech

$18.80

-0.65 (-3.34%)

, JNJ

Johnson & Johnson

$139.97

-0.54 (-0.38%)

05:15
12/11/19
12/11
05:15
12/11/19
05:15
Recommendations
XBiotech, Johnson & Johnson analyst commentary  »

XBiotech price target…

XBIT

XBiotech

$18.80

-0.65 (-3.34%)

JNJ

Johnson & Johnson

$139.97

-0.54 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

TALO

Talos Energy

$25.79

0.41 (1.62%)

05:14
12/11/19
12/11
05:14
12/11/19
05:14
Hot Stocks
Talos Energy announces acquisition of Gulf of Mexico portfolio »

Talos Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCC

Clarivate Analytics

$16.90

-0.17 (-1.00%)

05:12
12/11/19
12/11
05:12
12/11/19
05:12
Initiation
Clarivate Analytics initiated  »

Clarivate Analytics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CONN

Conn's

$13.60

-6.91 (-33.69%)

05:10
12/11/19
12/11
05:10
12/11/19
05:10
Downgrade
Conn's rating change  »

Conn's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

VALE

Vale

$12.30

-0.08 (-0.65%)

05:06
12/11/19
12/11
05:06
12/11/19
05:06
Upgrade
Vale rating change  »

Vale upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$19.09

0.24 (1.27%)

05:05
12/11/19
12/11
05:05
12/11/19
05:05
Upgrade
TechnipFMC rating change  »

TechnipFMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDGJF

John Wood Group

$0.00

(0.00%)

05:05
12/11/19
12/11
05:05
12/11/19
05:05
Upgrade
John Wood Group rating change  »

John Wood Group upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ES

Eversource

$80.98

0.24 (0.30%)

05:01
12/11/19
12/11
05:01
12/11/19
05:01
Initiation
Eversource initiated  »

Eversource initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

AEE

Ameren

$74.58

0.6 (0.81%)

05:01
12/11/19
12/11
05:01
12/11/19
05:01
Initiation
Ameren initiated  »

Ameren initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMK

GenMark

$5.58

-0.04 (-0.71%)

05:00
12/11/19
12/11
05:00
12/11/19
05:00
Downgrade
GenMark rating change  »

GenMark downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRAY

Dentsply Sirona

$57.40

0.08 (0.14%)

04:59
12/11/19
12/11
04:59
12/11/19
04:59
Downgrade
Dentsply Sirona rating change  »

Dentsply Sirona…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCBI

Texas Capital

$61.90

-1.55 (-2.44%)

, IBTX

Independent Bank

$59.90

-1.74 (-2.82%)

04:56
12/11/19
12/11
04:56
12/11/19
04:56
Upgrade
Texas Capital, Independent Bank rating change  »

Texas Capital upgraded to…

TCBI

Texas Capital

$61.90

-1.55 (-2.44%)

IBTX

Independent Bank

$59.90

-1.74 (-2.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
William Blair insurance analyst to hold a luncheon meeting »

Insurance Analyst Adam…

QMCO

Quantum

$0.00

(0.00%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
Quantum management to meet with B. Riley FBR »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

TCBK

TriCo Bancshares

$39.02

0.24 (0.62%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
TriCo Bancshares management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

DMTK

DermTech

$12.90

-1.56 (-10.79%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
DermTech management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
Oppenheimer healthcare analysts to hold a KOL dinner meeting »

Analysts hold a Cardiac…

MIC

Macquarie Infrastructure

$42.82

-0.02 (-0.05%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
Macquarie Infrastructure management to meet with Suntrust »

Group Dinner with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
BTIG oil and tanker analysts to hold a roundtable »

Oil Flow & Tanker…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.